Study efficacy of everolimus on course of uveitis:

• obtain quiescence of inflammation after start of treatment
• duration to obtain quiescence of inflammation
• number of patients with quiescence of inflammation

occurence of new complications from uveitis

• course of visual acuity (LogMAR): percentage of patients with visual loss of 10 or more numbers on ETDRS as compared to baseline
• change of recurrence rate as compared to time before everolimus treatment
• occurence of recurrence after obtaining remission with everolimus treatment
• duration to occurence of recurrence o number of patients with recurrence
• corticosparing effect from everolimus
• number of patients without topical corticosteroids; number of patients with reduced topical corticosteroids (<3x/daily)
• number of patients without systemic corticosteroids; number of patients with reduced systemic corticosteroids (<10mg/daily)
• efficacy of uveitis within 12 months
• maintenance of remission after withdrawel of everolimus treatment at 12 months o course of cystoid macula edema (FLA, OCT)

Inclusion Criteria:

• endogenous intermediate or posterior uveitis
• no quiesence in previous 3 months under systemic and topical steroids or systemic cyclosporine A
• indication for steroid sparing therapy
• uveitis related vision threating complications
• negative pregnancy test
• effective contraception

Exclusion Criteria:

Ophthalmic parameters:

• silicone oil in anterior chamber of both eyes para- or intraocular corticosteroid injections within previous 8 weeks
• opacities of optic media that obscure visualization of anterior or posterior eye segments

General parameters:

• requirement for combined immunosuppression for systemic immune-mediated disease contraindication against everolimus or cyclosporine A
• positive tuberculine test (GT 10
• currently immunosuppressive therapy with immunosuppressive drug other than cyclosporine
• poor compliance
• known intolerance to medication